RE:RE:RE:RE:RE:First Patient Selected BioTeck wrote: Wow, you are a total moron. How am I putting anything down other than managements ability to deliver on time. You should spend more time learning about your investment instead of name calling. It is safe based on the last human trial. If you actually read the results you'd also know it wasn't "efficaous" (I'm assuming you meant efficacious). If it was, why would they be doing the same trial again? They think Shapiro botched the job and now they want someone else to do the same trial over again. Only thing that is going to raise the price is a deal or positive results in 2020. Till then, get used to .18-25 cents.
Bioteck, I have a medical background much more extensive than yours. First of all Sernova never really officially released the results from Shapiros trial. He did it himself in a manner to muddy the results. Also if you go to Sernova;s webpage there are slides that show insulin producing cells and capillary growth..... Shapiro just dumped a bunch of pancreatic tissue into the pouch. He had pancreatic enzymes, other tissues in the pouch .... unlike the present study whereby using purified islet cells. Did you see the sloppy job of surgery shapiro did? It looks like a great white shark bit the half the body of the patient.
Why would they do the same trail again? Shapiro's protocols , methods, and parameters to measure statistically significant levels of insulin were non existent. Poor study by an amateur who was looking out to make a name for himeself. Since the Pharma market is in the states predominantly, FDA approval is the gold standard for any new medical device or drug approval.
Your arguements are pathetic and personal. Any other questions?